Page Not found
Pharma industry global business services: Progressions, regressions, and disruptions
Pharma industry global business services: Progressions, regressions, and disruptions
PODCAST

Pharma industry global business services: Progressions, regressions, and disruptions

Rick Bertheaud and Vicki Phelan discuss how technology, cost, and geopolitics are impacting how life sciences companies are delivering their business services.

When KPMG first established its Life Sciences Global Business Services (GBS) Consortium in 2014, the average score of the member companies’ GBS maturity survey results was around a 3.0 on the 5.0 scale – about on par with survey participants in many other industries.

But analysis of the same group’s 2017 survey results, coupled with deep-dive discussions during the Consortium’s April 2017 meeting, demonstrated that technological advances, increased cost pressures, geopolitical disruption, and numerous other drivers are impacting how life sciences companies are delivering their business services.

In this podcast, Rick Bertheaud and Vicki Phelan, leaders in KPMG’s shared services and outsourcing advisory practice with focuses in the life sciences and pharma industry, sat down to discuss:

  • areas in which life sciences companies are progressing their GBS delivery model, including talent management, data analytics, commercial orientation, and process excellence
  • areas in which they’re regressing – such as enabling technology and service portfolio – and the reasons behind the changes
  • how the need for cost reduction and simplification in today’s highly disrupted operating environment is impacting business services delivery models and operations.

Learn more about KPMG's Global Business Services Maturity Research program.

Victoria Phelan

Victoria Phelan

Managing Director, Shared Services & Outsourcing, KPMG US